BioPharmSignal logoBioPharmSignal

Biotech News

Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit

Foghorn Therapeutics (FHTX)Foghorn TherapeuticsCompany update

WATERTOWN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the

Related news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FATEFate Therapeutics2026-07-01 20:05 EST

Fate Therapeutics to Participate in Upcoming Third Quarter 2026 Conferences

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

KYMRKymera2026-06-24 20:01 EST

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

ELVNEnliven Therapeutics2026-06-15 20:40 EST

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

KYMRKymera2026-07-28 20:01 EST

Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026

CGEMCullinan Therapeutics, Inc.2026-07-28 11:00 EST

Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

View all latest news

Foghorn Therapeutics

Foghorn Therapeutics is an oncology company focused on chromatin biology and gene-regulation targets. Its platform seeks to create differentiated cancer therapies through epigenetic control.

Recent company news

FHTXFoghorn Therapeutics2026-08-06 11:00 EST

Foghorn Therapeutics Provides Second Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-06-05 11:00 EST

Foghorn Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026

FHTXFoghorn Therapeutics2026-05-12 11:00 EST

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

FHTXFoghorn Therapeutics2026-05-07 11:00 EST

Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update

FHTXFoghorn Therapeutics2026-04-21 20:05 EST

Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting

Stock data

Close
7.07 USD
Market cap
213.13M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States